Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II.
Haase
Michael
M
Department of Nephrology, University and Teaching Hospitals, Humboldt Univeristy of Berlin, Germany. michael.haase@charite.de
Bellomo
Rinaldo
R
Rocktaeschel
Jens
J
Ziemer
Sabine
S
Kiesewetter
Holger
H
Morgera
Stanislao
S
Neumayer
Hans-H
HH
D000925:Anticoagulants / Q000627:therapeutic use*; D000077425:Fondaparinux; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011134:Polysaccharides / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology*; D013927:Thrombosis / Q000188:drug therapy; D016896:Treatment Outcome
D000925:Anticoagulants; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux